A B S T R A C T A chemotactic factor inactivator (CFI) has been found in extracts of Walker and Novikoff tumor cells maintained in rats. The CFI directly inactivates the bacterial chemotactic factor as well as the leukotactic activity (for both neutrophils and monocytes) associated with C3 and C5 fragments and with culture fluids of lectin-stimulated lymphoid cells. The inactivation of the bacterial chemotactic factor is temperature and pH dependent. Subcellular fractionation procedures indicate that CFI is largely associated with the microsomal and cytosol fractions of tumor cells. CFI activity is also found in rat neutrophils, alveolar macrophages, and in extracts of liver, spleen, and kidney from normal animals. CFI derived from normal tissues also directly inactivates the bacterial chemotactic factor and has the ability to inactivate chemotactic activity associated with C3 and C5 fragments. A feature of the tumor-associated CFI is its presence in ascitic fluids of animals bearing tumor cells and the relative absence of any CFI activity in acute inflammatory exudates. The finding of the tumor-associated CFI may explain, at least in part, the tendency of malignant tumor cells to suppress cellular inflammatory reactions.
INTRODUCTION
There is abundant evidence to indicate that cellular inflammatory responses are defective in humans who bear malignancies unrelated to the hematopoetic system (1) (2) (3) (4) . The extent to which a causal relationship exists between defective cellular inflammatory responses and ineffective control of malignant tumors by the host is not presently known. Since lymphocytes and monocytes participate in cytotoxic reactions directed towards tumor cells (reviewed, 5) , it is not difficult to understand how the inability to accumulate these leukocytes in the vicinity of tumor cells might lead to difficulties in the control of tumors. The well known observations that adenocarcinomas of the breast carry a much better prognosis if associated with infiltrates of lymphocytes and monocytes, contrasted with similar tumors that incite little or no inflammatory cellular response, would seem to emphasize the importance of the inflammatory response in the control of tumors (6) .
Although it seems widely agreed that a significant number of patients with malignancies fail to express inflammatory reactions of the delayed hypersensitivity type, the belief that this defect is limited to the expression of delayed hypersensitivity reactions has been questioned inasmuch as agents (such as crotin oil) that do not demonstrably require an immunological mechanism for the expression of their inflammation-producing activity also fail to incite cellular inflammatory reactions in the skin of tumor-bearing patients (7) . These observations would tend to suggest a defect involving more than the immune apparatus. Recently, observations have been published describing the ability of tumor cells to "repel" macrophages (8) . In the same studies, it was suggested that tumor cells fail to incite cellular inflammatory responses in skin when compared with nontumor cells. Similar observations were reported several years ago by other investigators who used a cotton thread implanted in vivo into a bed of connective tissue containing, or devoid of, transplantable tumor cells. Quite consistently, the cellular inflammatory response to the foreign body was suppressed in the presence of malignant tumor cells (9) . All of these findings have suggested that malignant cells somehow prevent the inflammatory cellular response and accumulation of leukocytes.
In the studies to be reported in this paper, a leukotactic defect due to a tumor cell product is described. Tumor cells contain a chemotactic factor inactivator (CFI) 1 that inactivates C3, C5, bacterial, and lympho-activator can be isolated from many normal tissues. These studies may explain why cellular inflammatory responses are defective in the face of malignant tumors and why malignant tumors fail to incite cellular inflammatory responses.
METHODS
Leukotactic assays. These were performed in vitro with modified Boyden chambers containing micropore filters of 0.65 Am. In each experiment assays were carried out using both rabbit and rat neutrophils obtained by intraperitoneal injection of glycogen (10) . The results were similar regardless of the species of cell employed. The leukotactic assay has been described in detail elsewhere (11) . Leukocytes were suspended in Hanks' medium containing 0.1% bovine serum albumin.
Leukotactic factors. The bacterial chemotactic factor present in a culture medium (50 pAI) after overnight growth of Escherichia coli was employed (12) . This factor is heat stable and resists boiling. Where various extracts or fluids were tested for their ability to inhibit the bacterial chemotactic factor, the usual volume of test material was added to 50 ,ul bacterial factor, incubated for 30 min at 37°C at pH 7.3 (0.01 M Tris buffer), and then the residual chemotactic activity assessed by diluting the mixture to 1.0 ml with Hanks' medium. Details are given where this protocol was modified.
The chemotactic factors derived from the third (C3) and the fifth (C5) components of complement were also used in some experiments. These were obtained by appropriate trypsin treatment of purified human C3 and C5 (13) . In a given experiment, the equivalent of 20 ug intact C3 and C5 was used.
Tumor cells. Walker carcinosarcoma cells and Novikoff hepatoma cells, kindly supplied by Dr. I. Wodinsky (Arthur D. Little, Inc., Cambridge, Mass.), were maintained in the ascitic form in outbred Long-Evans rats, with serial passage, using 5 X 106 cells approximately every 7 days. When cell disruption techniques were employed, a "Biosonic" probe device (Bronwill Scientific, Rochester, N. Y.) was used. Sonication time and intensity were adjusted such that cell disruption occurred, but many nuclei remained intact (as monitored by light microscopy). Tissue homogenates were prepared according to previous techniques (14) . Leukocytes. In some experiments sonicates of rat neutrophils and alveolar macrophages were used. The former cells were obtained 5-6 h after intraperitoneal injection of 0.1% glycogen in saline. Alveolar macrophages were obtained as a pool from 5-10 rats after exsanguination from the inferior vena cava and wash-out of the trachealbronchical tree with saline (15) . Subcellular fractionation. Disruption of tumor cells suspended in Hanks' medium was carried out by sonication, as described above, followed by sedimentation of cell homogenates in a discontinuous gradient of sucrose, as' described by de Duve (16) . The success of the subcellular fractionation was assessed by partitioning of enzymes as described elsewhere (17) . Both enzyme assays and electron-microscopic analysis indicated the anticipated separation of subcellular constitutents.
Monocyte chemotaxis. Monocytic leukocytes were obtained from oil-induced peritoneal exudates in rats. For chemotactic testing, cells were suspended in minimal essential medium (MEM) containing 10% homologous serum. Micropore filters of 5-nm pore size were used. Factors employed were the C3 and C5 fragments and culture fluids (diluted 1: 5) from rat lymphoid cells stimulated with conconavalin A. Details are given in a recent report (13 (Table I) . From each of four different rats, the extracts from cell equivalents of 5 X 10' tumor cells inactivated between 62-100% of the chemotactic activity. The ability of Walker cell extract to inactivate the bacterial chemotactic factor was studied as a function of the temperature of incubation. In two 2 In this and subsequent sections reference is made to the CFI and chemotactic factor inhibitor. As will be shown, the inhibitor is in fact functioning as an inactivator. The terms are, thus, interchangeable. different experiments the degree of inactivation of bacterial chemotactic factor was directly proportional to the temperature (Table II) . At 00C virtually no inactivation occurred, whereas maximal effect over the temperature range studied was at 37°C.
Specificity of tumor-associated CFI activity. To determine if the inactivator from Walker tumor cells was restricted to an effect on the bacterial chemotactic factor, an extract from the tumor cells was incubated with the complement-dependent C3 and C5 chemotactic fragments and the amount of inactivation of the chemotactic activity determined. As shown in Table III , there was a consistent inactivation of all three chemotactic factors by the tumor cell extract. This is similar to the spectrum of activity of the CFI isolated from whole human serum (13) . As will be described below, extracts of other tissues and cells also contained an inactivator of chemotactic factors. (16) , and each subcellular fraction was compared with the original crude cell homogenate for ability to inactivate the bacterial chemotactic factor. The subcellular fractions included preparations of nuclei, mitochondria, lysosomes, microsomes, and the cytosol fraction. p-glucuronidase was maximal in the microsomal and lysosomal fractions with half as much activity in the cytosol fraction and virtually no activity in other subcellular fractions. Glucose-6-phosphatase was present in high amounts in the microsomal fraction, and virtually none was found in other subcellular fractions. Acid phosphatase was maximal in the cytosol fraction, but approximately one-third of the same amount was found in the lysosomal fraction and half again as much in the cytosol fraction. The partitioning of enzymes represents the anticipated fractionation (16) . As is evident from the data in Table  IV , high degrees of inactivation of chemotactic activity occurred with the crude homogenate, the microsomal fraction, and the cytosol fraction; whereas much less inactivation of the chemotactic activity occurred when the nuclear, mitochondrial, and lysosomal fractions were used. Table VIII , also led to the conclusion that the extracts were blocking the chemotactic factor rather than the indicator cells (neutrophils) in the assay system. There was complete inactivation of the chemotactic activity when the extracts were incubated with the bacterial chemotactic factor, whereas addition of the extract to the cells employed in the assay system led to very little loss in chemotactic activity (Table VIII , 0-10%). The combined data in Tables VII and VIII strongly suggest that inhibition of the chemotactic system by the extracts involves a direct interaction with the chemotactic factor(s). These inhibitors seem to be related functionally to the CFI that is present in low concentrations in human serum (13) . Ability of tumor cell CFI to inactivate monocyte chemotactic factors. As demonstrated above, CFI isolated from tumor cells will inactivate neutrophil chemotactic activity present in the fragments of C3 and C5, as well as the bacterial chemotactic factor. The same complement-dependent preparations were tested before and after incubation with the CFI-rich extract from Walker tumor cells, according to the details given in CF1 activity in peritoneal fluids. Ascitic fluids from either Novikoff or Walker tumor cell-bearing rats were collected 6 days after intraperitoneal innoculation with tumor cells and tested for CFI activity. A third group of rats was injected with 20 ml 0.1% glycogen in saline and the exudates (which were rich in neutrophils) were harvested 5-6 h later. Each fluid was tested for CFI activity. The results of these studies, given in (20) . It has been pointed out that, on the basis of the CFI findings, the "anergic" state in Hodgkins' patients may represent a defect in the effector limb of inflammation, and this abnormality would not be limited to monocytes and lymphocytes but would also involve all cells under leukotactic control (20) . In the same study reports in the literature were cited to indi-cate that in Hodgkins' disease the defect in expression of cellular inflammation is not limited to monocytes and lymphocytes, but also involves neutrophils (20) . Thus, the association of CFI with malignant tumors in the rat may have local as well as systemic blocking effects on the cellular expression of the inflammatory response.
Although the mechanisms by which serum-derived CFI and tumor-associated CFI react with chemotactic factors are not known, attempts have been made to determine if the interaction between CFI and the C5 chemotactic fragments involves a binding between the two reactants. No increase was found in the sedimentation velocity of the radiolabeled C5 fragment after its inactivation by CFI, suggesting that the mechanism of inactivation does not involve a stable union between inhibitor (CFI) and chemotactic factor (18) . It is known that the C3 and C5 anaphylatoxin fragments, which also possess chemotactic activity, are inactivated by the anaphylatoxin inactivator of human serum. The anaphylatoxin inactivator is a carboxypeptidase enzyme, is identical with the classical kininase of bradykinin, and inactivates both the C3 and C5 fragments as well as bradykinin by cleavage of the C-terminal arginine from each peptide (21) . We have recently demonstrated that preparations of CFI inactivate bradykinin (as determined by bioassay), and that this inactivation is associated with hydrolysis of the peptide (22) . In contrast to the anaphylatoxin inactivator, preparations of CFI lead to more extensive hydrolysis of bradykinin. Evidence for this conclusion comes from the release of arginine, phenylalanine, and proline (22) . It is possible that the kininase activity in CFI may be due to more than one enzyme, each having similar physical-chemical parameters, but it is clear that more than a simple carboxypeptidase B-type of activity is being measured. Admittedly there is no direct evidence that the kininase activity of CFI relates to its ability to inactivate chemotactic factors, but the kininase activity, as was the case with the anaphylatoxin inactivator, may provide some clue as to the mechanism of CFI action. The solution to the problem awaits the availability of adequate amounts of highly purified chemotactic factors.
That the enzymatic activity of CFI on peptides has certain restrictions has been shown by the finding that neither angiotensin I nor angiotensin II is hydrolyzed by CFI (22) . Furthermore, two CFI's can be isolated from human serum, one with a "substrate" specificity for the C3 chemotactic fragment, while the other CFI selectively inactivates the C5 chemotactic fragment. Thus, it now seems reasonable to postulate that CFI acts by enzymatic hydrolysis of chemotactic factor, and that a certain degree of substrate specificity is present.
Two papers have appeared in the literature describing the ability of soluble or particulate extracts of tumor cells to alter cell function. In the first case, a dializable factor was found in tumor fluids. This substance had the ability to inhibit adhesion of L cells as well as pseudopodia formation (23) . The second paper demonstrated that extracts from tumor cells, in some cases, cause inhibition of leukocyte migration when incubated with autologous or allogeneic blood leukocytes (24) . This latter finding might be related to the elaboration from lymphoid cells of a migration inhibitory factor. Thus, while both reports describe the ability of tumor cell extracts to alter functions of other cells and while such effects may be of biological significance, those reports differ significantly from the data presented in this paper in that CFI reacts with chemotactic factors and has no demonstrable direct effect on leukocytes. Thus, it must be concluded that products of tumor cells may very well affect both cellular as well as humoral factors in ways that are inimical to host defenses against tumor cells.
